INTERCEPT PHARMACEUTICALS, INC.·4

May 15, 4:46 PM ET

Genextra S.p.A. 4

4 · INTERCEPT PHARMACEUTICALS, INC. · Filed May 15, 2020

Insider Transaction Report

Form 4
Period: 2020-05-13
Transactions
  • Sale

    Common stock, par value $0.001 per share

    [F1]
    2020-05-13$84.60/sh595,578$50,385,8995,500,000 total
Footnotes (1)
  • [F1]Genextra S.p.A. will apply the proceeds from the sale to reduce outstanding indebtedness under its margin loan secured by its shares of Intercept's common stock, and for general corporate purposes.
Signature
/s/ Paolo Fundaro, Chief Financial Officer|2020-05-15

Documents

1 file
  • 4
    primary_doc.xmlPrimary

    PRIMARY DOCUMENT